Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eratrectinib
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Eratrectinib (VC004) is a next-generation, small-molecule oral tropomyosin receptor kinase (TRK) inhibitor independently developed by Jiangsu Vcare PharmaTech. It is designed to treat adult and adolescent patients (12 years and older) with solid tumors harboring NTRK gene fusions, specifically those with locally advanced or metastatic disease. As a next-generation inhibitor, eratrectinib aims to provide superior efficacy over first-generation TRK inhibitors and address secondary drug resistance mutations. The drug has received priority review designation from China's NMPA, where its New Drug Application (NDA) has been officially accepted, and it has an approved Investigational New Drug (IND) application from the US FDA.
- Other names
- VC004VC-004VC 004
02
Targets
NTRK2 (Tropomyosin-related kinase receptor type B)NTRK1 (Tropomyosin-related receptor kinase A)NTRK3 (Tropomyosin receptor kinase C)
Beyond the preview
Go deeper on eratrectinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eratrectinib.